TAE Life Sciences develops boron neutron capture therapy (BNCT), a particle therapy designed to selectively destroy cancer cells while sparing nearby healthy tissue. The company is led by Chief Scientific Officer Kendall Morrison and Chief Executive Officer Bruce Bauer. It intends to use new funding to move beyond the current boron-10 drug BPA and accelerate development of novel proprietary boron-10 target drugs. TAE is also refining its neutron beam accelerator technology for BNCT. The company has established a drug development facility in Santa Monica, Calif., with dedicated labs for cell biology and antibody production, medicinal chemistry, and molecular biology. The business is headquartered in Foothill Ranch, Calif. TAE Life Sciences is a Foothill Ranch, CA-based medical technology company and a majority-owned subsidiary of TAE Technologies developing an accelerator-based platform for clinical investigation of Boron Neutron Capture Therapy (BNCT). The company aims to leverage TAE Technologies’ accelerator-based neutron beam technology to bring treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult to treat with traditional methods. Its device is currently for investigational use only and has not been approved for sale or commercial use. TAE Life Sciences plans to work with clinical research partners, become a primary supplier of neutron beams for BNCT, and accelerate development of proprietary beam systems toward regulatory clearance for routine patient treatment. The company has announced a partnership with Neuboron Medtech, Ltd., and will deliver its neutron beam system to Neuboron for the first medical installation. TAE Life Sciences is led by CEO Bruce Bauer, PhD, and its governance includes executives from TAE Technologies and representation from its lead investor.

Total raised

$70M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2020